Pain Clinical Trials

Pregabalin (Lyrica) in the Management of Oral Mucositis Pain in Head/Neck Chemoradiation Therapy Patients

Double-blind, randomized, single-center pilot study to assess the effectiveness of pregabalin (Lyrica) in the management of mucositis pain in head and neck cancer.

testweb

zcscsa

testing_settings_upenn  

testing_settings_upenn 

Variability in Response to Non-steroidal Anti-inflammatory Drugs

The purpose of this research study is to measure the difference in response to non-steroidal anti-inflammatory drugs (NSAIDs) among people. We will also study what factors, like age, sex, or genetic background, cause these differences.

Normal Donor Human Bone Marrow Donation for Research

We are looking for healthy volunteers to donate bone marrow for research purposes. The Stem Cell & Xenograft Core provides bone marrow to laboratories on Penn’s campus researching leukemia and other blood disorders

CAROTID REVASCULARIZATION AND MEDICAL MANAGEMENT FOR ASYMPTOMATIC CAROTID STENOSIS TRIAL (CREST-2) PROTOCOL  

CREST-2 is a national multicenter stroke prevention study that is actively enrolling participants with narrowing in their carotid artery WITHOUT stroke or stroke warning signs (TIAs or mini-strokes). This study is comparing intensive medical management alone to intensive medical management used in combination with a procedure to remove plaque buildup …

Opioid Taper in Chronic Pain

If so, you may be eligible to participate in a paid research study looking to evaluate how the perception of pain changes as opioid medication is tapered. To learn more about this study contact research coordinator Lizette at 215-615-0512 or complete the form below to be contacted within 24 hours.

Evaluation of Corneal Confocal Microscopy in Ocular Surface Disease and/or Neuropathic Pain Patients

The populations to be studied for this study will be patients that are 18 years or older and have been diagnosed with ocular surface disease, such as dry eye, neurotrophic keratopathy, corneal neuralgia or neuropathic pain. Patients excluded from this study will be those who are members of the vulnerable …

An Open-Label Phase 2 Proof or Concept Study in Patients with C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated with ACH-0144471

The renal biopsy must occur no more than 30 days before the first dose, but will be targeted to occur approximately two weeks prior to the first dose of ACH-0144471.

Protocol Title: An Open-label Phase 2 Proof-of-Concept Study in Patients with C3 Glomerulopathy (C3G) or Immune- Complex Membranoproliferative Glomerulonephritis (ICMPGN) Treated with ACH-0144471 (ACH471-205)